ValenzaBio is a privately held clinical-stage biopharmaceutical company developing safe, effective, and differentiated therapies for autoimmune and inflammatory diseases. The company’s pipeline of monoclonal antibodies features best-in-class properties, targeting clinically validated mechanisms, and will provide improved treatment options for patients.

bacillus

Explore our lead product candidates

VB421

An anti-IGF-1R monoclonal antibody with a lead indication for thyroid eye disease

more
thyroid eye disease picture

VB119

An anti-CD19 monoclonal antibody currently enrolling clinical trials in renal autoimmune indications

more
thyroid eye disease picture

VB517

An anti-c-KIT monoclonal antibody with a lead indication for chronic urticaria

more
thyroid eye disease picture
bacillus bacillus
pretty woman smiling

WORKING AT VALENZABIO

There’s never been a better time to join us!

View open positions